M. Deininger

发表

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C

P. Paschka, D. Hossfeld, H. Gschaidmeier, 2003, Leukemia.

FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib

U. Reinhold, D. Niederwieser, M. Deininger, 2003, Leukemia.

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells

L. Honigberg, B. Druker, M. Deininger, 2008, Leukemia.

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

W. Siegert, J. Lipton, D. Niederwieser, 2003, Leukemia.

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

E. Jabbour, A. Hochhaus, M. Deininger, 2011, Leukemia.

Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells

J. Melo, B. Druker, A. Corbin, 2005, Leukemia.

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography

B. Druker, M. Heinrich, L. McGreevey, 2004, Leukemia.

High Bad and Bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML)

D. Hasenclever, D. Niederwieser, R. Krahl, 2002, Leukemia.

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

Jennifer L. Snead, B. Druker, E. Traer, 2012, Leukemia.

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia

T. O'hare, M. Deininger, C. Eide, 2015, Leukemia.

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

G. Hampton, L. Amler, Y. Guan, 2016, Leukemia.

A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib

M. Heinrich, A. Corbin, S. Willis, 2005, Leukemia.

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib

B. Druker, M. Heinrich, M. Deininger, 2007, Leukemia.

The second international congress on myeloproliferative and myelodysplastic syndromes.

J. Bennett, R. Silver, R. Silverstein, 2004, Leukemia research.

BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning

R. Brand, D. Niederwieser, U. Hegenbart, 2004, Leukemia.

The function of the pleckstrin homology domain in BCR–ABL-mediated leukemogenesis

J. Tyner, T. O'hare, M. Deininger, 2010, Leukemia.

e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants?

P. Paschka, G. Martinelli, A. Hochhaus, 2005, Leukemia.

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

G. Superti-Furga, O. Hantschel, I. Kaupe, 2008, Leukemia.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

C. Schiffer, R. Larson, M. Baccarani, 2020, Leukemia.

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia

K. Bhalla, J. Shearstone, D. Shrieve, 2017, Leukemia.

Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene

J. Melo, M. Deininger, J. Goldman, 2001, Genes, chromosomes & cancer.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

R. Larson, R. Baron, M. Baccarani, 2014, Cancer cell.

Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR

D. Niederwieser, M. Cross, H. Al-Ali, 2008, Leukemia.

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy

M. Deininger, M. Deininger, P. Shami, 2012, Leukemia.

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

B. Druker, M. Heinrich, C. Corless, 2008, Leukemia.

What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?

P. Manley, M. Deininger, 2012, Leukemia research.

Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR

J. Radich, F. McCormick, M. Unger, 2009, Leukemia.

The susceptibility of Philadelphia chromosome positive cells to FAS‐mediated apoptosis is not linked to the tyrosine kinase activity of BCR‐ABL

J. Melo, J. Goldman, M. Deininger, 1998, British journal of haematology.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

R. Baron, R. Moriggl, T. O'hare, 2017, Leukemia.

Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation

B. Druker, H. Erickson, J. Tyner, 2009, Leukemia.

Ph-positive and -negative myeloproliferative syndromes may co-exist

M. Loriaux, M. Mauro, M. Deininger, 2004, Leukemia.

Zev N. Kronenberg, Z. Kronenberg, B. Dalley, 2016, Leukemia.

High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia

H. Erickson, J. Tyner, M. Loriaux, 2009, Leukemia.